Bone Biologics Corp. Net Debt/EBITDA

Net Debt/EBITDA of BBLG for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending September 30, 2022 was 4.15 (a -64.3% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA decreased by -11314.32%
  • Annual Net Debt/EBITDA for 2021 was 6.06 (a -142.65% decrease from previous year)
  • Annual Net Debt/EBITDA for 2020 was -14.21 (a 207.86% increase from previous year)
  • Annual Net Debt/EBITDA for 2019 was -4.62 (a 60.12% increase from previous year)
Visit stockrow.com/BBLG for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of Bone Biologics Corp.

Most recent Net Debt/EBITDAof BBLG including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of Bone Biologics Corp.

Bone Biologics Corp. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 4.15 11.62 8.86
2021 -0.04 -55.55 -53.85 -65.51 6.06
2020 -56.8 -79.54 -86.85 -14.21
2019 0.0 -4.62
2018 -2.88
2017 -2.87
2016 -0.4

Business Profile of Bone Biologics Corp.

Sector: Healthcare
Industry: Medical Devices